Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
trending now
trending in pharma/biotech
trending in device
pharmagather
advertise
Legal Help
login/register
You are here
Home
»
companies
» JNJ
JNJ
Pa. State Judge orders new trial in J&J pelvic mesh case
Pa. State Judge orders new trial in J&J pelvic mesh case
Mass Device
JNJ
devices
pelvic mesh
Ethicon
Flag link:
In another try at lung cancer niche, J&J nabs a potential Tagrisso rival for $50M-plus
In another try at lung cancer niche, J&J nabs a potential Tagrisso rival for $50M-plus
Endpoints
JNJ
Tagrisso
AstraZeneca
Yuhan
Flag link:
[video+transcript]How Geron's Horrible Year Is a Great Reminder to Investors
[video+transcript]How Geron's Horrible Year Is a Great Reminder to Investors
Motley Fool
Geron
JNJ
imetelstat
Flag link:
Johnson & Johnson drops OSE’s rheumatoid arthritis drug
Johnson & Johnson drops OSE’s rheumatoid arthritis drug
Fierce Biotech
JNJ
OSE Immuotherapeutics
FR104
autoimmune disease
rheumatoid arthritis
Flag link:
Questions Raised About Invokana Label Expansion For CV Risk Reduction
Questions Raised About Invokana Label Expansion For CV Risk Reduction
Forbes
Janssen
JNJ
Invokana
type 2 diabetes
Flag link:
Johnson & Johnson bags long-awaited cardiovascular nod for diabetes drug Invokana
Johnson & Johnson bags long-awaited cardiovascular nod for diabetes drug Invokana
Fierce Pharma
JNJ
Invokana
type 2 diabetes
Flag link:
Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion
Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion
CP Wire
Arrowhead Pharmaceuticals
Janssen
JNJ
hepatitis B
Flag link:
Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion
Arrowhead Pharmaceuticals
Janssen
JNJ
Flag link:
Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial
Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial
BioSpace
JNJ
Janssen
Genmab
Darzalex
clinical trials
Multiple Myeloma
Flag link:
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients
CP Wire
Janssen
JNJ
Symtuza
HIV
Flag link:
Johnson & Johnson to open JLabs virtual networking pod in Philadelphia
Johnson & Johnson to open JLabs virtual networking pod in Philadelphia
Fierce Biotech
JNJ
JLabs
JPod
innovation
Flag link:
Janssen Unveils Positive Ph III Results for Symtuza in HIV-1 Patients
Janssen
JNJ
Symtuza
HIV
Flag link:
Zytiga generics looming as US court nixes J&J patent
Zytiga generics looming as US court nixes J&J patent
Pharmaforum
JNJ
Zytiga
generics
prostate cancer
Flag link:
J&J steps up vaccines R&D—and preps for launches—with €72M plant
J&J steps up vaccines R&D—and preps for launches—with €72M plant
Fierce Pharma
JNJ
vaccines
drug manufacturing
Flag link:
Bayer plans filings for prostate cancer drug darolutamide
Bayer plans filings for prostate cancer drug darolutamide
Pharmaforum
Bayer
darolutamide
prostate cancer
Pfizer
JNJ
Flag link:
Stelara Shines in Three Year Crohn's Disease Study
Stelara Shines in Three Year Crohn's Disease Study
CP Wire
Janssen
JNJ
Stelara
Crohn's Disease
clinical trials
Flag link:
Stelara Shines in Three Year Crohn's Disease Study
Jannsen
JNJ
Stelara
Crohn's Disease
Flag link:
J&J makes $2.1 billion offer to buy out Japan cosmetics firm Ci:z
J&J makes $2.1 billion offer to buy out Japan cosmetics firm Ci:z
CNBC
JNJ
M&A
Japan
Flag link:
J&J touts latest immune response data for 'mosaic' HIV vaccine program
J&J touts latest immune response data for 'mosaic' HIV vaccine program
Fierce Pharma
JNJ
vaccines
HUV
Africa
Flag link:
Bay Area's Biotech Talent Crisis Puts Job Seekers in the Driver's Seat
Bay Area's Biotech Talent Crisis Puts Job Seekers in the Driver's Seat
BioSpace
JNJ
San Francisco
Bay Area
JLabs
biotech
Flag link:
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »